Trial reportPloS one2012
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Innate Lymphoid Cells in the Central Nervous System.Frontiers in immunology · 2022Review
- The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies.Health science reports · 2022Review
- Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors.ACS nano · 2020Article
- Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.International journal of molecular sciences · 2020Review
- Rps27a might act as a controller of microglia activation in triggering neurodegenerative diseases.PloS one · 2020Article
- The Central Nervous System Contains ILC1s That Differ From NK Cells in the Response to Inflammation.Frontiers in immunology · 2019Article
- CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation.European journal of immunology · 2016Article
- Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis.Frontiers in immunology · 2015Review
- Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.Clinical and experimental immunology · 2014Review
- The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis.Multiple sclerosis international · 2014Review
- Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?The EPMA journal · 2013Article
- The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.American journal of stem cells · 2013Article
- Article
- The role of natural killer cells in multiple sclerosis and their therapeutic implications.Frontiers in immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitoxantrone is one of the few drugs approved for the treatment of progressive multiple sclerosis (MS). However, the prolonged use of this potent immunosuppressive agent is limited by the appearance of severe side effects. Apart from its general cytotoxic effect, the mode of action of mitoxantrone on the immune system is poorly understood. Thus, to develop safe therapeutic approaches for patients with progressive MS, it is essential to elucidate how mitoxantrone exerts it benefits. Accordingly, we initiated a prospective single-arm open-label study with 19 secondary progressive MS patients. We investigated long-term effects of mitoxantrone on patient peripheral immune subsets using flow cytometry. While we corroborate that mitoxantrone persistently suppresses B cells in vivo, we show for the first time that treatment led to an enrichment of neutrophils and immunomodulatory CD8(low) T cells. Moreover, sustained mitoxantrone applications promoted not only persistent NK cell enrichment but also NK cell maturation. Importantly, this mitoxantrone-induced NK cell maturation was seen only in patients that showed a clinical response to treatment. Our data emphasize the complex immunomodulatory role of mitoxantrone, which may account for its benefit in MS. In particular, these results highlight the contribution of NK cells to mitoxantrone efficacy in progressive MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.